U.S. FDA extends review of Humacyte blood vessel implant
Humacyte U.S. health regulator said it has expanded the company’s authority to test an implant that can replace a damaged or injured blood vessel, causing its shares to fall more than 15% after the close of trading.
POPULAR POSTS
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVE STREAM